Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,007 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Completed No phase listed Observational

Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease

NCT00566670
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 14, 2026, 10:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

NCT01101269
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ACEI or ARB, Lisinopril
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 14, 2026, 10:29 AM EDT
Active, not recruiting Phase 2 Interventional

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

NCT02713269
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Near Infrared Fluorescence Imaging for Bladder Cancer Detection

NCT03058705
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate HCL, Near Infrared Fluorescence (NIRF)
Drug · Device
Lead sponsor
Edward Messing
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Phase 1 Interventional Results available

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

NCT02275156
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 14, 2026, 10:29 AM EDT
Recruiting Phase 2 Interventional

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

NCT06263153
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Durvalumab, Futibatinib, Magnetic Resonance Imaging, Radical Cystectomy
Procedure · Biological · Drug
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Not applicable Interventional

Optimizing Cardiovascular Health and Physical Function in Hemodialysis Patients Through Volume Control and Exercise

NCT02627066
View directory record Official record
Conditions
Renal Failure
Interventions
Volume Control, Volume Control + Exercise
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
20 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Phase 1 Interventional

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822
View directory record Official record
Conditions
Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
Ciforadenant, Ciforadenant + atezolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Tucson, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 14, 2026, 10:29 AM EDT
Enrolling by invitation Not applicable Interventional

The Mindful Kidney: Supporting Mindfulness for Adults With Chronic Kidney Disease

NCT07541495
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Mindfulness
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Active, not recruiting Not applicable Interventional

Potassium Citrate and Crystal Light Lemonade

NCT05389995
View directory record Official record
Conditions
Kidney Stone
Interventions
Potassium citrate, Crystal light, Potassium citrate + crystal light
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Completed No phase listed Observational

Cardiovascular Mortality Associated With Abnormal Calcium Metabolism

NCT00018395
View directory record Official record
Conditions
Cardiovascular Disease, Kidney Disease
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

NCT00019539
View directory record Official record
Conditions
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
Interventions
bevacizumab, thalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Patiromer in Heart Failure Patients

NCT00868439
View directory record Official record
Conditions
Hyperkalemia, Heart Failure
Interventions
patiromer, placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Miami, Florida • Port Charlotte, Florida • Peoria, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Not applicable Interventional

Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)

NCT04227977
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
JuxtaFlow System
Device
Lead sponsor
3ive Labs
Industry
Eligibility
22 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Cleveland, Ohio • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 14, 2026, 10:29 AM EDT
Recruiting No phase listed Observational

Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

NCT04829357
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Intervention
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
1
States / cities
North Wales, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Phase 2Phase 3 Interventional

Phase 2/3 Oxabact Study

NCT01037231
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Oxalobacter formigenes, Placebo
Biological · Drug
Lead sponsor
OxThera
Industry
Eligibility
2 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Phase 4 Interventional

Arterial pH and Total Body Nitrogen Balances in APD

NCT00586131
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 14, 2026, 10:29 AM EDT
Not listed Phase 2 Interventional

An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients

NCT00834301
View directory record Official record
Conditions
Hyperphosphatemia, Inflammation, Renal Disease
Interventions
Oral Multivitamin
Dietary Supplement
Lead sponsor
Nephrian
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Simi Valley, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Oct 14, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 14, 2026, 10:29 AM EDT
Not listed Phase 2 Interventional

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

NCT03961698
View directory record Official record
Conditions
Breast Cancer, Renal Cell Carcinoma
Interventions
IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 14, 2026, 10:29 AM EDT
Active, not recruiting No phase listed Observational

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Withdrawn Not applicable Interventional

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

NCT05114057
View directory record Official record
Conditions
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis, Neonatal Sepsis
Interventions
Renal Angina Index (RAI)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Autonomic and Renal Contributions to Hypertension With ADT

NCT07848828
View directory record Official record
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions
Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 10:29 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 10:29 AM EDT